Net Income (Loss) Attributable to Parent in USD of aTYR PHARMA INC from 2013 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
aTYR PHARMA INC quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2013 to Q3 2025.
  • aTYR PHARMA INC Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was -$25,744,000.000, a 49.2% decline year-over-year.
  • aTYR PHARMA INC Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was -$75,122,000.000, a 17.7% decline year-over-year.
  • aTYR PHARMA INC annual Net Income (Loss) Attributable to Parent for 2024 was -$64,023,000.000, a 27.1% decline from 2023.
  • aTYR PHARMA INC annual Net Income (Loss) Attributable to Parent for 2023 was -$50,389,000.000, a 11.1% decline from 2022.
  • aTYR PHARMA INC annual Net Income (Loss) Attributable to Parent for 2022 was -$45,338,000.000, a 34.3% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)

aTYR PHARMA INC Quarterly Net Income (Loss) Attributable to Parent (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 -$75,122,000 -$25,744,000 -$8,485,000 -49.2% 01 Jul 2025 30 Sep 2025 10-Q 06 Nov 2025
Q2 2025 -$66,637,000 -$19,531,000 -$3,225,000 -19.8% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025
Q1 2025 -$63,412,000 -$14,880,000 +$611,000 +3.9% 01 Jan 2025 31 Mar 2025 10-Q 07 May 2025
Q4 2024 -$64,023,000 -$14,967,000 -$207,000 -1.4% 01 Oct 2024 31 Dec 2024 10-K 13 Mar 2025
Q3 2024 -$63,816,000 -$17,259,000 -$5,919,000 -52.2% 01 Jul 2024 30 Sep 2024 10-Q 06 Nov 2025
Q2 2024 -$57,897,000 -$16,306,000 -$3,968,000 -32.2% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025
Q1 2024 -$53,929,000 -$15,491,000 -$3,540,000 -29.6% 01 Jan 2024 31 Mar 2024 10-Q 07 May 2025
Q4 2023 -$50,389,000 -$14,760,000 -$7,239,000 -96.2% 01 Oct 2023 31 Dec 2023 10-K 13 Mar 2025
Q3 2023 -$43,150,000 -$11,340,000 +$1,904,000 +14.4% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024
Q2 2023 -$45,054,000 -$12,338,000 +$82,000 +0.66% 01 Apr 2023 30 Jun 2023 10-Q 13 Aug 2024
Q1 2023 -$45,136,000 -$11,951,000 +$202,000 +1.7% 01 Jan 2023 31 Mar 2023 10-Q 02 May 2024
Q4 2022 -$45,338,000 -$7,521,000 +$1,038,000 +12.1% 01 Oct 2022 31 Dec 2022 10-K 13 Mar 2025
Q3 2022 -$46,376,000 -$13,244,000 -$5,577,000 -72.7% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023
Q2 2022 -$40,799,000 -$12,420,000 -$2,029,000 -19.5% 01 Apr 2022 30 Jun 2022 10-Q 09 Aug 2023
Q1 2022 -$38,770,000 -$12,153,000 -$5,002,000 -69.9% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023
Q4 2021 -$33,768,000 -$8,559,000 -$3,627,000 -73.5% 01 Oct 2021 31 Dec 2021 10-K 14 Mar 2024
Q3 2021 -$30,141,000 -$7,667,000 -$1,068,000 -16.2% 01 Jul 2021 30 Sep 2021 10-Q 14 Nov 2022
Q2 2021 -$29,073,000 -$10,391,000 -$3,945,000 -61.2% 01 Apr 2021 30 Jun 2021 10-Q 15 Aug 2022
Q1 2021 -$25,128,000 -$7,151,000 -$8,904,000 -5.1% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022
Q4 2020 -$16,224,000 -$4,932,000 +$1,041,000 +17.4% 01 Oct 2020 31 Dec 2020 10-K 14 Mar 2023
Q3 2020 -$17,265,000 -$6,599,000 -$954,000 -16.9% 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021
Q2 2020 -$16,311,000 -$6,446,000 -$598,000 -10.2% 01 Apr 2020 30 Jun 2020 10-Q 11 Aug 2021
Q1 2020 -$15,713,000 $1,753,000 +$7,890,000 01 Jan 2020 31 Mar 2020 10-Q 14 May 2021
Q4 2019 -$23,603,000 -$5,973,000 +$349,000 +5.5% 01 Oct 2019 31 Dec 2019 10-K 26 Mar 2020
Q3 2019 -$23,952,000 -$5,645,000 +$1,469,000 +20.6% 01 Jul 2019 30 Sep 2019 10-Q 13 Nov 2020
Q2 2019 -$25,421,000 -$5,848,000 +$4,564,000 +43.8% 01 Apr 2019 30 Jun 2019 10-Q 13 Nov 2020
Q1 2019 -$29,985,000 -$6,137,000 +$4,530,000 +42.5% 01 Jan 2019 31 Mar 2019 10-Q 13 Nov 2020
Q4 2018 -$34,515,000 -$6,322,000 +$5,152,000 +44.9% 01 Oct 2018 31 Dec 2018 10-K 26 Mar 2020
Q3 2018 -$39,667,000 -$7,114,000 +$4,076,000 +36.4% 01 Jul 2018 30 Sep 2018 10-K 26 Mar 2020
Q2 2018 -$43,743,000 -$10,412,000 +$1,726,000 +14.2% 01 Apr 2018 30 Jun 2018 10-K 26 Mar 2020
Q1 2018 -$45,469,000 -$10,667,000 +$2,738,000 +20.4% 01 Jan 2018 31 Mar 2018 10-K 26 Mar 2020
Q4 2017 -$48,207,000 -$11,474,000 +$1,092,000 +8.7% 01 Oct 2017 31 Dec 2017 10-K 26 Mar 2019
Q3 2017 -$49,299,000 -$11,190,000 +$2,629,000 +19% 01 Jul 2017 30 Sep 2017 10-K 26 Mar 2019
Q2 2017 -$51,928,000 -$12,138,000 +$3,245,000 +21.1% 01 Apr 2017 30 Jun 2017 10-K 26 Mar 2019
Q1 2017 -$55,173,000 -$13,405,000 +$2,682,000 +16.7% 01 Jan 2017 31 Mar 2017 10-K 26 Mar 2019
Q4 2016 -$57,855,000 -$12,566,000 +$3,927,000 +23.8% 01 Oct 2016 31 Dec 2016 10-K 20 Mar 2018
Q3 2016 -$61,782,000 -$13,819,000 -$2,490,000 -22% 01 Jul 2016 30 Sep 2016 10-K 20 Mar 2018
Q2 2016 -$59,292,000 -$15,383,000 -$4,303,000 -38.8% 01 Apr 2016 30 Jun 2016 10-K 20 Mar 2018
Q1 2016 -$54,989,000 -$16,087,000 -$7,016,000 -77.3% 01 Jan 2016 31 Mar 2016 10-K 20 Mar 2018
Q4 2015 -$47,973,000 -$16,493,000 -$10,455,000 -1.7% 01 Oct 2015 31 Dec 2015 10-K 16 Mar 2017
Q3 2015 -$37,518,000 -$11,329,000 -$4,698,000 -70.8% 01 Jul 2015 30 Sep 2015 10-K 16 Mar 2017
Q2 2015 -$32,820,000 -$11,080,000 -$5,492,000 -98.3% 01 Apr 2015 30 Jun 2015 10-K 16 Mar 2017
Q1 2015 -$27,328,000 -$9,071,000 -$2,978,000 -48.9% 01 Jan 2015 31 Mar 2015 10-K 16 Mar 2017
Q4 2014 -$24,350,000 -$6,038,000 01 Oct 2014 31 Dec 2014 10-K 30 Mar 2016
Q3 2014 -$6,631,000 01 Jul 2014 30 Sep 2014 10-K 30 Mar 2016
Q2 2014 -$5,588,000 01 Apr 2014 30 Jun 2014 10-K 30 Mar 2016
Q1 2014 -$6,093,000 01 Jan 2014 31 Mar 2014 10-K 30 Mar 2016

aTYR PHARMA INC Annual Net Income (Loss) Attributable to Parent (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 -$64,023,000 -$13,634,000 -27.1% 01 Jan 2024 31 Dec 2024 10-K 13 Mar 2025
2023 -$50,389,000 -$5,051,000 -11.1% 01 Jan 2023 31 Dec 2023 10-K 13 Mar 2025
2022 -$45,338,000 -$11,570,000 -34.3% 01 Jan 2022 31 Dec 2022 10-K 13 Mar 2025
2021 -$33,768,000 -$17,544,000 -1.1% 01 Jan 2021 31 Dec 2021 10-K 14 Mar 2024
2020 -$16,224,000 $0 0% 01 Jan 2020 31 Dec 2020 10-K 14 Mar 2023
2019 -$16,224,000 +$18,291,000 +53% 01 Jan 2019 31 Dec 2019 10-K 14 Mar 2023
2018 -$34,515,000 +$13,692,000 +28.4% 01 Jan 2018 31 Dec 2018 10-K 24 Mar 2021
2017 -$48,207,000 +$9,648,000 +16.7% 01 Jan 2017 31 Dec 2017 10-K 26 Mar 2020
2016 -$57,855,000 -$9,882,000 -20.6% 01 Jan 2016 31 Dec 2016 10-K 26 Mar 2019
2015 -$47,973,000 -$23,623,000 -97% 01 Jan 2015 31 Dec 2015 10-K 20 Mar 2018
2014 -$24,350,000 -$4,336,000 -21.7% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017
2013 -$20,014,000 01 Jan 2013 31 Dec 2013 10-K 30 Mar 2016
* An asterisk sign (*) next to the value indicates that the value is likely invalid.